Status: Recruiting
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Participants needed: 244
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Taiho Pharmaceutical Co., Ltd.Updated: Mar 3, 2026Locations: 21
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 [+19]
Investigational agents or anticancer therapy within 5 half-lives prior to the fi... [+6]